When someone develops a blood cancer like acute myeloid leukemia after years of working around benzene, the urge to blame the chemical is natural. But in a court of law, blame is not enough. The entire case rests on a single question: did benzene exposure actually cause this specific person’s illness? That question depends on causation, and causation is the battleground where many toxic tort claims are won or lost.
Benzene is a known carcinogen. The scientific community agrees that prolonged exposure to benzene can cause certain blood cancers, especially acute myeloid leukemia and other myelodysplastic syndromes. That is the easy part. The hard part is connecting that general scientific knowledge to one individual plaintiff. In legal terms, the court needs two layers of proof: general causation and specific causation. General causation asks whether benzene is capable of causing the type of cancer the plaintiff has. Specific causation asks whether benzene did cause it in this particular case, given that person’s exposure history, genetics, and other risk factors.
Courts do not let plaintiffs simply say “I worked with benzene, and now I have leukemia.” That is anecdote, not evidence. Instead, the plaintiff must present expert testimony from epidemiologists, toxicologists, and medical doctors. These experts rely on studies that compare large groups of benzene-exposed workers to unexposed populations. They look at dose–response relationships, meaning higher and longer exposure leads to higher risk. They also look at latency periods, because benzene-related leukemia typically appears several years or even decades after first exposure. All of this helps the court decide whether the chemical is a plausible cause of the disease.
But specific causation demands more than a plausible story. The expert must tie the exposure level to the patient’s medical history. For example, if a worker spent twenty years in a refinery where benzene was used as a solvent, and he has no family history of leukemia, and he never smoked, the argument gets stronger. On the other hand, if the same worker was only exposed to trace amounts of benzene while wearing protective gear, or if he also received radiation therapy for another cancer years earlier, the defense will seize on those competing causes. The plaintiff does not have to prove benzene was the only cause, but the law in most states requires that benzene was a substantial contributing factor. That means the exposure must have increased the risk enough to matter, not just by a tiny fraction.
Judges act as gatekeepers for this expert testimony. Under the standard known as Daubert, which applies in federal courts and many state courts, the judge must decide whether the expert’s methodology is sound and generally accepted in the scientific community. This is a critical hurdle. A plaintiff’s expert cannot just say “I believe” or “I have seen similar cases.” The expert must show that their conclusions are based on reliable data, not on speculation or personal opinion. Defense attorneys often challenge the reliability of causation experts, arguing that the studies cited are too weak, or that the exposure levels in those studies are much higher than what the plaintiff actually encountered.
One of the biggest fights in benzene litigation involves quantitative exposure. Many workplaces did not keep precise records of how much benzene a particular worker breathed in over the years. The plaintiff may have to rely on industrial hygiene estimates, job descriptions, and the testimony of former coworkers. These estimates are imprecise, and the defense will exploit that imprecision. If the plaintiff cannot show that their exposure approached levels associated with cancer in published studies, the judge may throw out the case before it ever reaches a jury. This is why skilled attorneys need to build a detailed exposure history, sometimes hour by hour, for every job site over several decades.
Another challenge is the latency problem. Imagine a worker who was exposed to benzene in the 1980s, then left the industry, and was diagnosed with leukemia in 2020. The long gap looks suspicious to a jury. But benzene-related cancers often take ten to forty years to develop. An expert can explain this using biological evidence about how benzene damages bone marrow and causes genetic mutations that eventually lead to uncontrolled cell growth. However, the longer the gap, the more room for the defense to argue that something else, like aging or lifestyle factors, caused the disease.
Ultimately, winning a benzene blood cancer claim is about telling a coherent story backed by solid science. The plaintiff must show that benzene can cause their type of cancer, that they were exposed to a meaningful amount, that the timing fits, and that there are no other obvious culprits. No single piece of evidence seals the deal. It is a cumulative process, like assembling a puzzle where every piece must snap into place. And because the stakes are high—medical bills, lost wages, and long-term suffering—courts demand real proof, not fear or suspicion. That is the reality for any toxic tort case, and it is especially true for benzene claims, where the science is strong but the facts of each individual case are often messy, incomplete, and fiercely contested.
